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Background
Th e omega-3 (n-3) fatty acids docosahexaenoic acid and 
eicosapentaenoic acid, along with γ-linolenic acid and 
antioxidants, may modulate systemic inﬂ ammatory res-
ponse and improve oxygenation and outcomes in patients 
with acute lung injury.
Methods
Objective: To determine if dietary supplementation of 
these substances to patients with acute lung injury would 
increase ventilator-free days to study day 28.
Design: Th e OMEGA study, a randomized, doubleblind, 
placebo-controlled, multicenter trial conducted from 
January 2, 2008, through February 21, 2009. All partici-
pants had complete follow-up.
Setting: Th is trial occurred at 44 hospitals in the National 
Heart, Lung, and Blood Institute ARDS Clinical Trials 
Network.
Subjects: Participants were 272 adults within 48 hours of 
developing acute lung injury requiring mechanical 
ventilation whose physicians intended to start enteral 
nutrition.
Intervention: Twice-daily enteral supplementation of n-3 
fatty acids, γ -linolenic acid, and antioxidants compared 
with an isocaloric control. Enteral nutrition, directed by a 
protocol, was delivered separately from the study 
supplement.
Outcomes: Ventilator-free days to study day 28.
Results
Th e study was stopped early for futility after 143 and 129 
patients were enrolled in the n-3 and control groups. 
Despite an 8-fold increase in plasma eicosapentaenoic 
acid levels, patients receiving the n-3 supplement had 
fewer ventilator-free days (14.0 vs 17.2; P=.02) (diﬀ erence, 
−3.2 [95% CI, −5.8 to −0.7]) and intensive care unit–free 
days (14.0 vs 16.7; P=.04). Patients in the n-3 group also 
had fewer nonpulmonary organ failure–free days (12.3 vs 
15.5; P=.02). Sixty-day hospital mortality was 26.6% in 
the n 3 group vs 16.3% in the control group (P=.054), and 
adjusted 60-day mortality was 25.1% and 17.6% in the n-3 
and control groups, respectively (P=.11). Use of the n-3 
supplement resulted in more days with diarrhea (29% vs 
21%; P=.001).
Conclusions
Twice-daily enteral supplementation of n-3 fatty acids, γ-
linolenic acid, and antioxidants did not improve the 
primary end point of ventilator-free days or other clinical 
outcomes in patients with acute lung injury and may be 
harmful.
Commentary
Interest in the use of immunomodulation through 
nutrition for patients with Acute Lung Injury (ALI) came 
to attention after a 1999 article by Gadek et al 
demonstrated an increase in 28-day ventilator free days 
(VFD), reduction of intensive care unit (ICU) length of 
stay and new organ failure when enteral diets were 
supplemented with omega-3 fatty acid, γ-linolenic acid 
(GLA), and antioxidants1. Subsequent studies have had 
similar ﬁ ndings. A 2006 study by Pontes-Arruda et al. 
demonstrated a similar increase in VFDs, increase in ICU 
free days as well as a reported 19% absolute reduction in 
mortality with the use of the same enteral supplements 2. 
Another study in 2006, by Singer and colleagues, found 
an increase in oxygenation through this supplementation, 
but no change in ICU length of stay, VFDs or mortality 3. 
Th ese three studies became the basis of a meta-analysis © 2010 BioMed Central Ltd
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on the subject as well as the justiﬁ cation to provide a 
Grade A level recommendation by the Society of Critical 
Care Medicine (SCCM) and American Society for 
Parenteral and Enteral Nutrition (A.S.P.E.N.) to endorse 
the use of these enteral supplements in patients with 
ALI 4,5, 6.
OMEGA sought to evaluate the primary endpoint of 
VFDs at 28 days through bolus supplementation of 
omega-3 fatty acids, GLA and antioxidants compared to 
no immunomodulation supplementation. OMEGA was a 
trial performed concurrently in a 2x2 factorial distribu-
tion with EDEN, a trial to assess diﬀ erences in full versus 
trophic enteral nutrition in patients with ALI. Patients in 
the OMEGA trial were randomized to receive twice daily 
supplementation or an iso-caloric control compound in 
addition to their baseline enteral nutrition. Using an 
intent-to-treat analysis, their results demon strate a 
statistically signiﬁ cant decrease in VFDs compared with 
the control arm as well as a trend toward increased 
mortality. Th eir results also did not demon strate any 
clinically or statistically signiﬁ cant improve ment in 
pulmonary function or physiology on ventilator support. 
Th is prompted the study’s data and safety monitoring 
board (DSMB) to stop the trial early for futility.
Although the study was ended early, it did provide 
signiﬁ cant ﬁ ndings in terms of enteral immunomodu la-
tion in the treatment of ALI. One of this study’s greatest 
strengths is its size. OMEGA was able to recruit and 
randomize 272 patients, compared to the 165 patients or 
fewer in each of the prior three studies, making it the 
largest to evaluate an eﬀ ect of enteral immunomodulaiton 
on ALI. Another signiﬁ cant strength of this study was the 
ability to demonstrate the biologic eﬀ ects of omega-3 
fatty acids, GLA and antioxidants. Th ey demonstrate 
(Figure 2 and eﬁ gure 2a, 2b) that serum levels of 
eicosapentaenoic acid did rise, but there was no change 
in the serum levels of measured inﬂ ammatory mediators, 
interleukins (IL) 6 and 8. Th e destination of these sub-
stances could be accounted for by a rise in urinary 
concentrations. Additionally, a 2x2 factorial analysis was 
performed to demonstrate no interaction between these 
arms of the study and those involved in the EDEN 
component (p=0.47).
Th is was a well done study without many weaknesses. 
Th ere was no beneﬁ t from enteral supplementation with 
omega-3 fatty acids, GLA and antioxidants, but there was 
statistical signiﬁ cance for decreased VFDs opposing the 
results from previously conducted studies. Another 
potential weakness is that this trial utilized bolus dosing 
opposed to continuous supplementation that was utilized 
in prior studies on the aﬀ ects of omega-3 fatty acids, 
GLA and antioxidants on ALI. Finally, the enriched 
supple ment appears to have a diﬀ erent composition 
(when converted to equivalent units of measurement) 
than the omega-3 fatty acids, GLA and antioxidants 
utilized in prior studies. Th ese points are not direct 
weakness inherent in this trial’s design, but rather limits 
external validation to previous studies.
Th e results of this study raise enough attention to 
question the foundations of the A.S.P.E.N. grade A 
recommendations to utilize enteral nutrition with 
omega-3 fatty acids, GLA and antioxidants in ALI. Th e 
strengths of this study are enough to reconsider practice 
guidelines to endorse their use in the treatment of ALI. 
While the idea of using enteral nutrition to modulate the 
immune seemed promising, other studies have subse-
quently showed little beneﬁ t, ranging from cardiovascular 
events, glycemic control or rates of infectious compli-
cations in critically ill patients as well as the primary care 
setting 7,8. Th e authors of the OMEGA study suggest that 
the changes seen in this trial, compared to the prior 
studies on the use of omega-3 fatty acids, GLA and 
antioxidants in ALI may have been the result of changes 
in non-experimental covariates, such as increased 
attention to ﬂ uid management and lung-protective venti-
la tion, as a result of the ARDSnet trials. Although 
omega-3 fatty acids, GLA and antioxidants substances 
appear to have good bioavailability, their physiologic 
eﬀ ects seem to be more as inert substrates than modiﬁ ers 
of inﬂ ammation as measured by this trial.
Recommendation
Although this study was ended early for futility to 
decrease VFDs through enteral supplementation with 
omega-3 fatty acids, GLA and antioxidants, it also raises 
concern for the potential for increased mortality. More-
over, it is rare that a single study greatly change practice 
patterns. Th e strongest conclusion made from this article 
is that these substrates do not decrease ventilator free 
days. Consequently, this article has enough merits to 
warrant a revision in the current guidelines which 
provide a grade A level recommendation to endorse the 
use of enteral omega-3 fatty acids, GLA and antioxidants 
in the treatment of ALI.
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